Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival

Yinghui Xu, Yanru Wang, Hongliang Liu, Qiong Shi, Dakai Zhu, Christopher I. Amos, Shenying Fang, Jeffrey E. Lee, Terry Hyslop, Xin Li, Jiali Han, Qingyi Wei

Research output: Contribution to journalArticle

Abstract

Metzincins are key molecules in the degradation of the extracellular matrix and play an important role in cellular processes such as cell migration, adhesion, and cell fusion of malignant tumors, including cutaneous melanoma (CM). We hypothesized that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-specific survival (CMSS). To test this hypothesis, we first performed Cox proportional hazards regression analysis to evaluate the associations between genetic variants of 75 metzincin metallopeptidase family genes and CMSS using the dataset from the genome-wide association study (GWAS) from The University of Texas MD Anderson Cancer Center (MDACC) which included 858 non-Hispanic white patients with CM, and then validated using the dataset from the Harvard GWAS study which had 409 non-Hispanic white patients with invasive CM. Four independent SNPs (MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G) were identified as predictors of CMSS, with a variant-allele attributed hazards ratio (HR) of 1.73 (1.32-2.29, 9.68E-05), 1.46 (1.15-1.85, 0.002), 1.68 (1.31-2.14, 3.32E-05) and 0.67 (0.51-0.87, 0.003), respectively, in the meta-analysis of these two GWAS studies. Combined analysis of risk genotypes of these four SNPs revealed a decreased CMSS in a dose-response manner as the number of risk genotypes increased (Ptrend< 0.001). An improvement was observed in the prediction model (area under the curve [AUC] = 81.4% vs. 78.6%), when these risk genotypes were added to the model containing non-genotyping variables. Our findings suggest that these genetic variants may be promising prognostic biomarkers for CMSS.

Original languageEnglish (US)
Pages (from-to)22-31
Number of pages10
JournalMolecular Carcinogenesis
Volume57
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Metalloproteases
Melanoma
Genome-Wide Association Study
Survival
Skin
Genes
Genotype
Single Nucleotide Polymorphism
Cell Fusion
Cell Adhesion
Area Under Curve
Cell Movement
Extracellular Matrix
Meta-Analysis
Neoplasms
Biomarkers
Alleles
Regression Analysis
Datasets

Keywords

  • cutaneous melanoma
  • cutaneous melanoma-specific survival (CMSS)
  • genome-wide association study (GWAS)
  • metzincins
  • single-nucleotide polymorphism (SNP)

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. / Xu, Yinghui; Wang, Yanru; Liu, Hongliang; Shi, Qiong; Zhu, Dakai; Amos, Christopher I.; Fang, Shenying; Lee, Jeffrey E.; Hyslop, Terry; Li, Xin; Han, Jiali; Wei, Qingyi.

In: Molecular Carcinogenesis, Vol. 57, No. 1, 01.01.2018, p. 22-31.

Research output: Contribution to journalArticle

Xu, Y, Wang, Y, Liu, H, Shi, Q, Zhu, D, Amos, CI, Fang, S, Lee, JE, Hyslop, T, Li, X, Han, J & Wei, Q 2018, 'Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival', Molecular Carcinogenesis, vol. 57, no. 1, pp. 22-31. https://doi.org/10.1002/mc.22716
Xu, Yinghui ; Wang, Yanru ; Liu, Hongliang ; Shi, Qiong ; Zhu, Dakai ; Amos, Christopher I. ; Fang, Shenying ; Lee, Jeffrey E. ; Hyslop, Terry ; Li, Xin ; Han, Jiali ; Wei, Qingyi. / Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. In: Molecular Carcinogenesis. 2018 ; Vol. 57, No. 1. pp. 22-31.
@article{ccae0f771f994fc2b0b9ff2b6ccbdf7d,
title = "Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival",
abstract = "Metzincins are key molecules in the degradation of the extracellular matrix and play an important role in cellular processes such as cell migration, adhesion, and cell fusion of malignant tumors, including cutaneous melanoma (CM). We hypothesized that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-specific survival (CMSS). To test this hypothesis, we first performed Cox proportional hazards regression analysis to evaluate the associations between genetic variants of 75 metzincin metallopeptidase family genes and CMSS using the dataset from the genome-wide association study (GWAS) from The University of Texas MD Anderson Cancer Center (MDACC) which included 858 non-Hispanic white patients with CM, and then validated using the dataset from the Harvard GWAS study which had 409 non-Hispanic white patients with invasive CM. Four independent SNPs (MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G) were identified as predictors of CMSS, with a variant-allele attributed hazards ratio (HR) of 1.73 (1.32-2.29, 9.68E-05), 1.46 (1.15-1.85, 0.002), 1.68 (1.31-2.14, 3.32E-05) and 0.67 (0.51-0.87, 0.003), respectively, in the meta-analysis of these two GWAS studies. Combined analysis of risk genotypes of these four SNPs revealed a decreased CMSS in a dose-response manner as the number of risk genotypes increased (Ptrend< 0.001). An improvement was observed in the prediction model (area under the curve [AUC] = 81.4{\%} vs. 78.6{\%}), when these risk genotypes were added to the model containing non-genotyping variables. Our findings suggest that these genetic variants may be promising prognostic biomarkers for CMSS.",
keywords = "cutaneous melanoma, cutaneous melanoma-specific survival (CMSS), genome-wide association study (GWAS), metzincins, single-nucleotide polymorphism (SNP)",
author = "Yinghui Xu and Yanru Wang and Hongliang Liu and Qiong Shi and Dakai Zhu and Amos, {Christopher I.} and Shenying Fang and Lee, {Jeffrey E.} and Terry Hyslop and Xin Li and Jiali Han and Qingyi Wei",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/mc.22716",
language = "English (US)",
volume = "57",
pages = "22--31",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival

AU - Xu, Yinghui

AU - Wang, Yanru

AU - Liu, Hongliang

AU - Shi, Qiong

AU - Zhu, Dakai

AU - Amos, Christopher I.

AU - Fang, Shenying

AU - Lee, Jeffrey E.

AU - Hyslop, Terry

AU - Li, Xin

AU - Han, Jiali

AU - Wei, Qingyi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Metzincins are key molecules in the degradation of the extracellular matrix and play an important role in cellular processes such as cell migration, adhesion, and cell fusion of malignant tumors, including cutaneous melanoma (CM). We hypothesized that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-specific survival (CMSS). To test this hypothesis, we first performed Cox proportional hazards regression analysis to evaluate the associations between genetic variants of 75 metzincin metallopeptidase family genes and CMSS using the dataset from the genome-wide association study (GWAS) from The University of Texas MD Anderson Cancer Center (MDACC) which included 858 non-Hispanic white patients with CM, and then validated using the dataset from the Harvard GWAS study which had 409 non-Hispanic white patients with invasive CM. Four independent SNPs (MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G) were identified as predictors of CMSS, with a variant-allele attributed hazards ratio (HR) of 1.73 (1.32-2.29, 9.68E-05), 1.46 (1.15-1.85, 0.002), 1.68 (1.31-2.14, 3.32E-05) and 0.67 (0.51-0.87, 0.003), respectively, in the meta-analysis of these two GWAS studies. Combined analysis of risk genotypes of these four SNPs revealed a decreased CMSS in a dose-response manner as the number of risk genotypes increased (Ptrend< 0.001). An improvement was observed in the prediction model (area under the curve [AUC] = 81.4% vs. 78.6%), when these risk genotypes were added to the model containing non-genotyping variables. Our findings suggest that these genetic variants may be promising prognostic biomarkers for CMSS.

AB - Metzincins are key molecules in the degradation of the extracellular matrix and play an important role in cellular processes such as cell migration, adhesion, and cell fusion of malignant tumors, including cutaneous melanoma (CM). We hypothesized that genetic variants of the metzincin metallopeptidase family genes would be associated with CM-specific survival (CMSS). To test this hypothesis, we first performed Cox proportional hazards regression analysis to evaluate the associations between genetic variants of 75 metzincin metallopeptidase family genes and CMSS using the dataset from the genome-wide association study (GWAS) from The University of Texas MD Anderson Cancer Center (MDACC) which included 858 non-Hispanic white patients with CM, and then validated using the dataset from the Harvard GWAS study which had 409 non-Hispanic white patients with invasive CM. Four independent SNPs (MMP16 rs10090371 C>A, ADAMTS3 rs788935 T>C, TLL2 rs10882807 T>C and MMP9 rs3918251 A>G) were identified as predictors of CMSS, with a variant-allele attributed hazards ratio (HR) of 1.73 (1.32-2.29, 9.68E-05), 1.46 (1.15-1.85, 0.002), 1.68 (1.31-2.14, 3.32E-05) and 0.67 (0.51-0.87, 0.003), respectively, in the meta-analysis of these two GWAS studies. Combined analysis of risk genotypes of these four SNPs revealed a decreased CMSS in a dose-response manner as the number of risk genotypes increased (Ptrend< 0.001). An improvement was observed in the prediction model (area under the curve [AUC] = 81.4% vs. 78.6%), when these risk genotypes were added to the model containing non-genotyping variables. Our findings suggest that these genetic variants may be promising prognostic biomarkers for CMSS.

KW - cutaneous melanoma

KW - cutaneous melanoma-specific survival (CMSS)

KW - genome-wide association study (GWAS)

KW - metzincins

KW - single-nucleotide polymorphism (SNP)

UR - http://www.scopus.com/inward/record.url?scp=85037052580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037052580&partnerID=8YFLogxK

U2 - 10.1002/mc.22716

DO - 10.1002/mc.22716

M3 - Article

VL - 57

SP - 22

EP - 31

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 1

ER -